Okuda Kenji, Wada Yoshiyuki, Shimada Masaru
Department of Molecular Biodefense Research, Yokohama City University Graduate School of Medicine, Yokohama, Kanagawa Prefecture 236-0004, Japan.
Choju Medical Institute, Toyohashi, Aichi Prefecture 441-8124, Japan.
Vaccines (Basel). 2014 Jan 13;2(1):89-106. doi: 10.3390/vaccines2010089.
The advantages of genetic immunization of the new vaccine using plasmid DNAs are multifold. For example, it is easy to generate plasmid DNAs, increase their dose during the manufacturing process, and sterilize them. Furthermore, they can be stored for a long period of time upon stabilization, and their protein encoding sequences can be easily modified by employing various DNA-manipulation techniques. Although DNA vaccinations strongly increase Th1-mediated immune responses in animals, several problems persist. One is about their weak immunogenicity in humans. To overcome this problem, various genetic adjuvants, electroporation, and prime-boost methods have been developed preclinically, which are reviewed here.
使用质粒DNA进行新型疫苗基因免疫的优势是多方面的。例如，质粒DNA易于制备，在生产过程中可以增加其剂量，并且能够进行灭菌处理。此外，经稳定化处理后它们可以长期保存，而且通过各种DNA操作技术可以轻松修改其蛋白质编码序列。尽管DNA疫苗接种能在动物体内强烈增强Th1介导的免疫反应，但仍存在一些问题。其中之一是它们在人体内的免疫原性较弱。为克服这一问题，临床前已开发出各种基因佐剂、电穿孔法和初免-加强免疫方法，本文对此进行综述。
